Clinical trial
Phase I Clinical Trial of Caring Cross Anti-CD19/20/22 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia) (C3PO)
NCT07166419 is registered in ClinicalTrials.gov with Ohio State University Comprehensive Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I Clinical Trial of Caring Cross Anti-CD19/20/22 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia) (C3PO)
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- January 14, 2026
- Completion date
- December 31, 2026
- Enrollment
- 24 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
blast phase chronic myeloid leukemia, bcr-abl1 positive, recurrent acute lymphoblastic leukemia, recurrent chronic lymphocytic leukemia, recurrent chronic myeloid leukemia, bcr-abl1 positive, recurrent indolent non-hodgkin lymphoma, recurrent lymphoblastic lymphoma, recurrent non-hodgkin lymphoma, recurrent transformed chronic lymphocytic leukemia, refractory acute lymphoblastic leukemia, refractory chronic lymphocytic leukemia, refractory chronic myeloid leukemia, bcr-abl1 positive, refractory indolent non-hodgkin lymphoma, refractory lymphoblastic lymphoma, refractory non-hodgkin lymphoma, refractory transformed chronic lymphocytic leukemia